Personalised cancer vaccine 45% effective at targeting tumours

Researchers have developed an effective vaccine that re-engineers cells from a patient’s tumour to target and destroy cancer cells. The results, published in the peer-reviewed Journal of Clinical Oncology, show that 45% of patients treated with an autologous cell vaccine, created from their own cancer cells, had a confirmed anti-tumour response. The findings provide more evidence for the effectiveness of advanced immunotherapy at treating cancer and the life-changing potential of advanced personalised cancer treatments.

During the study, 31 patients with advanced solid-state tumours (including breast, lung and prostate cancer) received treatment with an autologous cell vaccine. In total, each patient received six doses of the vaccine.

The results were highly encouraging, with the authors noting that there was a “confirmed anti-tumour response in the majority of patients treated.” In total, 45% of patients had a positive anti-tumour response, with the tumour either reducing in size or staying stable. Researchers noted that the ground-breaking vaccines created a “cytotoxic T-lymphocytic immune response against tumour cells antigens.”

Results also showed that the vaccine worked as a checkpoint inhibitor in 38.7% of patients. Co-author and RGCC Network Doctor, Professor Joachim Drevs: “In the last decade, cancer immunotherapy has emerged as the most promising anti-tumour approach. A big advantage of autologous vaccines along with the excellent efficacy is that they are easily prepared by using only a blood sample from the patient.”

Image credit: Dian Polekhina

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free